Dexmedetomidine for Sedation during Withdrawal of Support

Chris O’Hara, Robert F. Tamburro and Gary D. Ceneviva
Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State Hershey Children’s Hospital, Department of Pediatrics, Hershey, PA, USA.

ABSTRACT: Agents used to control end-of-life suffering are associated with troublesome side effects. The use of dexmedetomidine for sedation during withdrawal of support in pediatrics is not yet described. An adolescent female with progressive and irreversible pulmonary deterioration was admitted. Despite weeks of therapy, she did not tolerate weaning of supplemental oxygen or continuous bilevel positive airway pressure. Given her condition and the perception that she was suffering, the family requested withdrawal of support. Despite opioids and benzodiazepines, she appeared to be uncomfortable after support was withdrawn. Ketamine was initiated. Relief from ketamine was brief, and its use was associated with a “wide-eyed” look that was distressing to the family. Ketamine was discontinued and a dexmedetomidine infusion was initiated. The patient’s level of comfort improved greatly. The child died peacefully 24 hours after initiating dexmedetomidine from her underlying disease rather than the effects of the sedative.

KEYWORDS: palliative care, hypnotics and sedatives, dexmedetomidine, lung disease

Background
Opioids, benzodiazepines, ketamine, propofol, barbiturates, and neuroleptics are agents utilized to provide sedation to manage refractory pain and symptoms at the end of life. A recent retrospective analysis based on data from the Pediatric Health Information System and Premier Perspective Database between 2007 and 2011 confirmed this, and also noted an increasing use of dexmedetomidine. While patients receiving palliative sedation have been shown to survive longer than matched untreated cohorts, and opioids and benzodiazepines may prolong survival after withdrawal of support, the pharmacologic therapies used in these situations are associated with adverse effects. These include impaired communication, hypersalivation, respiratory depression, delirium, myoclonus, propylene glycol toxicity, and upper airway obstruction. The side effects of these agents may inhibit or delay a practitioner’s prescription or a family’s acceptance of their use. Moreover, families experience distress because their desire for continued interaction is often compromised by the agents used to treat end-of-life suffering.

Dexmedetomidine, a highly selective alpha, agonist, is being used with increasing frequency in pediatric patients for sedation. It has adverse effects which are known. It is a potent sedative that induces a state of non-Rapid Eye Movement (REM)-like sleep from which patients may be easily aroused rather than frank unconsciousness. It does not suppress the respiratory drive, and it has a wide range of useful actions, including sialoschesis, anxiolysis, analgesia, as well as prevention of recall. All of this would suggest that dexmedetomidine may be a very useful medication in the setting of palliative sedation or withdrawal of support. However, the literature regarding its use in palliative care is sparse.

Case Description
An adolescent female with severe developmental delay, spastic quadripareisis, obstructive sleep apnea, cortical blindness, scoliosis, renal disease, bilateral hip dislocation, chronic lung disease, and a seizure disorder was admitted for respiratory distress and worsening chronic respiratory failure. This was her sixth admission in a year, four of which were secondary to respiratory failure. Her need for respiratory support had progressively increased and now included nocturnal bilevel positive airway pressure (BiPAP) support, which frequently was used for 24 hours a day secondary to oxygen desaturations. Moreover, her ability to interact had declined to the point where she was now non-interactive except for her facial expressions, which her family perceived to indicate that she was suffering and in pain. Despite three weeks of aggressive pulmonary therapy, she was not able to tolerate weaning of supplemental oxygen or continuous BiPAP support. With no acute interceding illness, her lung disease was considered to be the result of a chronic, progressive, and irreversible process, which would ultimately result in her death. A multi-disciplinary meeting was convened during which all potential
treatment options were presented to the family. Her resuscitation status had been established previously as “Do Not Attempt Resuscitation/Do Not Intubate” during previous admissions. Given her progressive, irreversible pulmonary deterioration, the perception that she was suffering, and her declining level of interaction, the family opted to not pursue any additional life-sustaining therapies (eg, tracheostomy, spinal fusion) and requested withdrawal of BiPAP support. All members of the medical team concurred with what was seen as a reasonable request.

At the time of withdrawal, she was receiving scheduled enteral lorazepam and morphine with additional morphine doses as needed. When the BiPAP was removed, the patient was placed on a high-flow oxygen mask, and she initially appeared quite comfortable. Over time, however, she became increasingly tachypneic, and all concurred that additional treatment was needed. Consequently, intravenous ketamine (0.5 mg/kg) and midazolam (0.05 mg/kg) were added to her treatment regimen to achieve a level of sedation that would provide comfort. Although this therapy appeared to provide comfort, it was associated with a “wide-eyed” look, which was troubling to the family who perceived this as an indication of distress. Moreover, any benefit from the ketamine was short-lived, and her initial level of perceived discomfort promptly recurred. Consequently, the child received a dose of fentanyl (0.5 µg/kg) and a decision was made to begin dexmedetomidine. The initial rate of dexmedetomidine was 0.2 µg/kg/hour, and this was titrated to 0.4 µg/kg/hour. No bolus was administered. With these interventions, she appeared to be quite comfortable and remained so for 14 hours. At that point, she displayed increased work of breathing and was given a single breakthrough dose of enteral morphine (0.05 mg/kg). With this intervention, she remained comfortable for nearly four hours, at which point, she again appeared slightly uncomfortable. She received midazolam (0.05 mg/kg) intravenously, and the infusion rate of dexmedetomidine was increased to 0.7 µg/kg/hour. Approximately ten hours later, the patient died seemingly comfortable with no additional signs of distress.

Discussion

Dexmedetomidine would appear to hold great potential for use in end-of-life care. It is a potent sedative that also possesses analgesic and opioid sparing properties. Its sedative effects induce a state of non-REM like sleep fostering easy awakening if desired. It causes dose-dependent amnesia and may reduce the likelihood of delirium in comparison to benzodiazepines. Moreover, it is reported to possess anxiolytic and antiasialogogue properties. Each of these effects further suggests that it may be a useful medication in the setting of palliative sedation or sedation used during withdrawal of support. Despite these purported benefits, potential side effects must be considered before dexmedetomidine is used as primary therapy in palliative sedation. For example, dexmedetomidine exhibits pro-arrhythmogenic properties, specifically bradycardia; there are reports of bradycardia-related death in patients being treated with dexmedetomidine. Additional cardiovascular complications include asystole, pacemaker noncapture, brief sinus pause, prolongation of the QT interval, and PR intervals, and sinus arrest. While dexmedetomidine use has been associated with hypotension, particularly in relation to loading doses, Ebert et al demonstrated that higher doses may lead to increased blood pressure, but decreased cardiac output. Despite these potential adverse cardiovascular effects, dexmedetomidine has been widely used as a sedative in infants and children with congenital heart disease. Moreover, it has been used during the perioperative period of congenital cardiac surgery to treat atrial and junctional tachyarrhythmias.

Other factors may also temper the use of dexmedetomidine in palliative care. It is metabolized by the liver, and thus may be less safe in patients with hepatic insufficiency. It is almost exclusively cleared (95%) by the kidneys, and renal dosing adjustment has been suggested by some to avoid excessive sedation. Further, drug-induced adrenal insufficiency has been reported; however, data suggest that, at normal doses, this effect is related to abnormal adrenal corticotropic hormone (ACTH) stimulation and not steroidogenesis inhibition. Additionally, although the short-term benefits of dexmedetomidine are becoming more established, the safety of its long-term use has not been studied as extensively. Case reports and retrospective analyses suggest that infusions used for days to weeks are, in most cases, relatively safe and well tolerated. Although not consistently reported, withdrawal and tachyphylaxis for infusions lasting >24 hours have been described.

Despite these concerns and potential adverse effects, dexmedetomidine appears to offer some advantages when compared to other medications used in palliative sedation. In contrast to ketamine and its dissociative state, dexmedetomidine allows patients to be easily awakened. Depending on the degree of sedation, patients can awaken, interact with caregivers, and engage in complex cognitive tasks. Agents such as midazolam and propofol may require a dosing change to allow interaction. While not as effective as benzodiazepines, dexmedetomidine inhibits recall in a dose-dependent fashion. Unlike pentobarbital and benzodiazepines, dexmedetomidine has analgesic properties. Moreover, it has multiple administration advantages over propofol. Propofol causes pain on injection, whereas dexmedetomidine does not, and dexmedetomidine may be administered subcutaneously, broadening the scope of where it may be administered. Propofol also has variable compatibility with metoclopramide, midazolam, diazepam, and morphine—medications compatible with dexmedetomidine and commonly used in end-of-life care. Finally, the limited effects of dexmedetomidine on respiratory drive, combined with its lack of effect on upper airway patency, may make it safer than propofol, benzodiazepines, and opioids in end-of-life care.
Conclusion
This report is the first to describe the use of dexmedetomidine for sedation used in the withdrawal of support in a pediat-
ric patient. Patients who suffer from illnesses that are neither amenable to curative therapy nor effective symptom control are faced with immense suffering. The use of a sedative agent that induces a sleep-like state allowing rapid awakening, provides analgesia, alleviates anxiety, decreases oral secretions, does not suppress the respiratory drive, affect the airway, or induce delirium would appear to be an ideal medication for palliative sedation when life sustaining therapy for these indi-
viduals is withdrawn. Its compatibility with other medications used in end-of-life care may prove practical. Its use in sedation for withdrawal of support or palliation of intolerable suffering would appear to merit further prospective study.

Author Contributions
Conceived and designed the experiments: RT and GC. Wrote the first draft of the manuscript: CO, RT, and GC. Contributed to the writing of the manuscript: CO, RT, and GC. Agreed with manuscript results and conclusions: CO, RT, and GC. Made critical revisions and approved the final version: CO, RT, and GC. All the authors reviewed and approved the final manuscript.

REFERENCES
1. Zawistowski CA, DeVita MA. A descriptive study of children dying in the pediat-
ric intensive care unit after withdrawal of life-sustaining treatment. Pediatr Crit Care Med. 2004;5(3):216–223.
2. Angeleseco DL, Hamilton H, Faughnan LG, Johnson LM, Baker JN. Pediatric palliative sedation therapy with propofol: recommendations based on experience with children in terminal cancer. J Palliat Med. 2012;15(10):1082–1090.
3. Ragsdale L, Zhong W, Morrison W, et al. Pediatric exposure to opioid and sedation medications during terminal hospitalizations in the United States, 2007–2011. J Pediatr. 2015;166(3):587–593.e581.
4. Chau JD, Treece PD, Engelberg RA, et al. Narcotic and benzodiazepine use after with-
table death after ventilator withdrawal. J Pediatr. 2005;146(4):399–402.
5. Tsui BC, Davies D, Desai S, Malherbe S. Intravenous ketamine infusion as an 
adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma. J Pediatr Hematol Oncol. 2004;26(10):678–680.
6. Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and seda-
tives on survival in terminally ill cancer patients. J Pain Symptom Manage. 2001; 21(4):282–289.
7. Morita T, Inokata M, Asahi I, et al. Japan Pain, Rehabilitation, Palliative Medi-
icne, and Psycho-Oncology (J-PRPP) Study Group. Concerns of family mem-
bers of patients receiving palliative sedation therapy. J Palliat Med. 2009;12(1): 117–122.
8. Morita T, Kusunose J, Niozsa A, Guldsher LB, Thomas K, Eblert FA. Dex-
medetomidine related cardiac arrest in a patient with permanent pacemaker; a cautious note. Tae In Clin Electrophysiol. 2007;30(9):1158–1160.
9. Talke P, Chen R, Thomas B, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg. 2009;109(4):834–839.
10. Burns KM, Greene EA. Long QT syndrome unmasked by dexmedetomidine: a case report. Congenit Heart Dis. 2014;9(1):E11–E15.
11. Hammer GB, Drover DR, Cao H, et al. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg. 2008;106(1):79–83.
12. Peden CJ, Cloote AH, Stratford N, Scott-Cawson D, Roberts C. The effect of intravenous dex-
medetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil. Anesth Analg. 2001;93(5):408–413.
13. Tobias JD. Dexmedetomidine: applications in pediatric critical care and pedi-
atric anesthesiology. Pediatr Crit Care Med. 2007;8(2):115–131.
14. Chan JD, Treece PD, Engelberg RA, et al. Narcotic and benzodiazepine use after with-
table death after ventilator withdrawal: case report and review of the literature. Pharmaco-
therapy. 2009,29(12):1492.
15. Videira RL, Ferreira RM. Dexmedetomidine and asystole. Anesth Analg. 2004;101(4):1479. Author reply 1479–1480.
16. Shah AN, Konera J, Niozsa A, Guldsher LB, Thomas K, Ehlert FA. Dex-
medetomidine related cardiac arrest in a patient with permanent pacemaker: a cautious note. Tae In Clin Electrophysiol. 2007;30(9):1158–1160.
17. Talke P, Chen R, Thomas B, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg. 2009;109(4):834–839.
18. Burns KM, Greene EA. Long QT syndrome unmasked by dexmedetomidine: a case report. Congenit Heart Dis. 2014;9(1):E11–E15.
19. Hammer GB, Drover DR, Cao H, et al. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg. 2008;106(1):79–83.
20. Peden CJ, Cloote AH, Stratford N, Scott-Cawson D, Roberts C. The effect of intravenous dex-
medetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil. Anesth Analg. 2001;93(5):408–413.
21. Tobias JD. Dexmedetomidine: applications in pediatric critical care and pedi-
atric anesthesiology. Pediatr Crit Care Med. 2007;8(2):115–131.
22. Shank ES, Sheridan RL, Ryan CM, Keaney TJ, Martyn JA. Hemodynamic responses to dexmedetomidine in critically injured intubated pediatric burned patients: a preliminary study. J Burn Care Res. 2013;34(3):311–317.
23. Beijan S, Valasek C, Nigo JJ, Cleveland DC, Willis BC. Prolonged use of dex-
medetomidine in the paediatric cardiothoracic intensive care unit. Cardiol Young. 2009;19(1):98–104.
24. Finkel JC, Johnson YJ, Quezado ZM. The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children. Crit Care Med. 2005;33(9):2110–2112.
25. Chrysostomou C, Beckman L, Shidley D, Berry D, Morell VO, Munos R. Dex-
medetomidine: a novel drug for the treatment of atrial and junctional tachyar-
rhythmias during the perioperative period for congenital cardiac surgery: a prelimi-
inary study. Anesth Analg. 2008;107(5):1514–1522.
26. De Wolf AM, Frangen RJ, Avram MJ, Fitzgarrald PC, Rahimi-Danesh F. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impair-
ment. Anesth Analg. 2001;93(5):1205–1209.
27. Tucker EW, Cooke DW, Kudchadkar SR, Klaus SA. Dexmedetomidine infu-
sion associated with transient adrenal insufficiency in a pediatric patient: a case report. Case Rep Pediatr. 2013;2013:207907.
28. Maze M, Virtanen R, Daunt D, Banks SJ, Stover EP, Feldman D. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal ste-
roidogenesis: in vivo and in vitro studies. Anesthesiology. 1991;74(3):204–208.
29. Walker J, MacCannell M, Fischer C, Kopcha R, Sayhors R, McCaul J. Sedation using dexmedetomidine in pediatric burn patients. J Burn Care Res. 2006;27(2):206–210.
30. Enomoto Y, Kudo T, Saito T, et al. Prolonged use of dexmedetomidine in an infant with respiratory failure following living donor liver transplantation. Paa-
itic Anesthesiol. 2006;16(12):1285–1288.
31. Hammer GB, Philip BM, Schroeder AR, Rosen FS, Kohati P. Prolonged infu-
sion of dexmedetomidine for sedation following tracheal resection. Paediatr Anaesth. 2005;15(7):616–620.
42. Carney L, Kendrick J, Carr R. Safety and effectiveness of dexmedetomidine in the pediatric intensive care unit (SAD-PICU). *Can J Hosp Pharm*. 2013;66(1):21–27.

43. Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. *Anaesthesia*. 1999;54(12):1136–1142.

44. Everett LL, van Rooyen IF, Warner MH, Shortleff HA, Saneto RP, Ojemann JG. Use of dexmedetomidine in awake craniotomy in adolescents: report of two cases. *Paediatr Anaesth*. 2006;16(3):338–342.

45. Phan H, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. *Paediatr Drugs*. 2008;10(1):49–69.

46. Tobias JD. Subcutaneous dexmedetomidine infusions to treat or prevent drug withdrawal in infants and children. *J Opioid Manag*. 2008;4(4):187–191.

47. Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. *Am J Health Syst Pharm*. 1997;54(11):1287–1292.

48. Mahmoud M, Radhakrishnan R, Gunter J, et al. Effect of increasing depth of dexmedetomidine anesthesia on upper airway morphology in children. *Paediatr Anaesth*. 2010;20(6):506–515.